Vanguard ESG ETF Analysts See 11.26% Upside Potential

Investors eye Vanguard ESG U.S. Stock ETF as analysts forecast an 11.26% upside based on target prices. With notable price targets for holdings SASR, PCRX, and IMAX, the ETF's prospects may positively influence stock prices.

Date: 07-01-2025

AI Rating: 7

Implied Analyst Price Targets
The report provides valuable insights into the price targets set by analysts for the Vanguard ESG U.S. Stock ETF (ESGV) and its underlying holdings. The ETF is currently priced at $106.81, with an implied target price of $118.83 according to analysts, indicating an upside potential of 11.26% over the next 12 months. This optimistic outlook could reflect positively on investor sentiment.

Individual Holdings Outlook
Among the notable underlying holdings, Sandy Spring Bancorp Inc (SASR), Pacira BioSciences Inc (PCRX), and IMAX Corp. (IMAX) each showcase significant upside potential in their respective target prices. SASR has a recent trading price of $32.43, with a target of $37.00, representing a 14.09% upside. Similarly, PCRX is currently at $18.63 and has an average target of $21.25, which suggests a 14.06% increase. Lastly, IMAX is trading at $24.02, with an anticipated target of $27.32 – a 13.73% upside. The aggregate positivity surrounding these holdings may indeed influence stock prices positively in the coming year.

Investor Considerations
While the analysts' targets suggest optimism regarding the future performance of this ETF and its constituents, investors should remain cautious—high price targets can lead to sharp downgrades if market conditions change. Thus, continued monitoring of the performance of these holdings and general market trends is recommended before making investment decisions.

Stocks: ESGV SASR PCRX IMAX